Tariff Hikes On Chinese Imports Still In Play As US Plans December Increase
Trump administration negotiations with China representatives led to US suspending tariff increase to 25% on product categories announced set to begin 15 October. But 15% tariff added in September on about $112bn worth of Chinese goods remains and US still plans in December to impose separate 10% tariff hike on $160bn in other products.
You may also be interested in...
Essential oils no longer on list of products slated for EU tariff increases effective 18 October, a win for US fragrance industry facing uncertainty in tumultuous global trade climate. Fragrancy industry, like dietary supplement manufacturers, still face higher tariffs on imports from China as next round of hikes is scheduled to start 15 October.
Consumer health industry groups plan to comment at June 17 public hearing on USTR plan for 25% tariff on imports from China not included in three earlier rounds of duties. NPA applauds USTR for allowing exclusion process for imported products valued at $200bn already hit with tariffs in 2018.
FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."